We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Geron Corporation (GERN - Free Report) is scheduled to report second quarter 2016 results on Aug 3 after the market closes. The company’s first quarter 2016 loss was in-line with expectations. Let’s see how things are shaping up for the second quarter announcement.
Imetelstat Remains in Focus
With Geron being a development stage company, investor focus will remain on the company’s pipeline. Geron currently has one candidate in its pipeline, imetelstat, which is being developed in collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech.
Imetelstat is in a phase II study (IMbark) in patients with DIPSS intermediate-2 or high-risk myelofibrosis who have relapsed after or are refractory to a JAK inhibitor. An internal review, to determine the adequacy of one or both of the initial dosing arms, is slated for the second half of the year. Based on this review, a decision regarding the continuation/halting/modification of the dosing arms or the selection of alternative doses will be taken.
Imetelstat is in a phase II/III study (IMerge) as well for myelodysplastic syndrome (MDS). An internal review of this study is also expected in the second half of the year. Data from this internal review must support a positive assessment of the benefit risk profile of imetelstat in this patient population before Part 2 of the study, a phase III randomized placebo-controlled trial, can commence.
In addition to updates on imetelstat, investors will also be interested to know if Geron has made any progress in expanding its pipeline. The company is seeking to add new oncology candidates, programs or companies to its portfolio with its focus primarily on the hematology-oncology space.
Surprise History
Geron’s performance over the last four quarters is mixed with the company surpassing expectations in two quarter and meeting expectations in the other two quarters. The average surprise over the last four quarters is +17.81%.
Our proven model does not conclusively show that Geron is likely to beat earnings. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here, as you will see below.
Zacks ESP: Earnings Surprise Prediction or Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. Both the Most Accurate estimate and the Zacks Consensus Estimate for Geron are a loss of 7 cents per share.
Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks of #1, #2 and #3 have a significantly higher chance of beating earnings. The sell-rated stocks (#4 and #5) should never be considered going into an earnings announcement.
Other Stocks to Consider
Here are a couple of health care companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
The Earnings ESP for Exelixis, Inc. (EXEL - Free Report) is +3.70% and it carries a Zacks Rank #3. The company is expected to release second-quarter results on Aug 3.
Fate Therapeutics, Inc. (FATE - Free Report) has an Earnings ESP of +12.9% and carries a Zacks Rank #3. It is expected to release second-quarter results on Aug 3.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Geron Corporation (GERN - Free Report) is scheduled to report second quarter 2016 results on Aug 3 after the market closes. The company’s first quarter 2016 loss was in-line with expectations. Let’s see how things are shaping up for the second quarter announcement.
Imetelstat Remains in Focus
With Geron being a development stage company, investor focus will remain on the company’s pipeline. Geron currently has one candidate in its pipeline, imetelstat, which is being developed in collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech.
Imetelstat is in a phase II study (IMbark) in patients with DIPSS intermediate-2 or high-risk myelofibrosis who have relapsed after or are refractory to a JAK inhibitor. An internal review, to determine the adequacy of one or both of the initial dosing arms, is slated for the second half of the year. Based on this review, a decision regarding the continuation/halting/modification of the dosing arms or the selection of alternative doses will be taken.
Imetelstat is in a phase II/III study (IMerge) as well for myelodysplastic syndrome (MDS). An internal review of this study is also expected in the second half of the year. Data from this internal review must support a positive assessment of the benefit risk profile of imetelstat in this patient population before Part 2 of the study, a phase III randomized placebo-controlled trial, can commence.
In addition to updates on imetelstat, investors will also be interested to know if Geron has made any progress in expanding its pipeline. The company is seeking to add new oncology candidates, programs or companies to its portfolio with its focus primarily on the hematology-oncology space.
Surprise History
Geron’s performance over the last four quarters is mixed with the company surpassing expectations in two quarter and meeting expectations in the other two quarters. The average surprise over the last four quarters is +17.81%.
GERON CORP Price and EPS Surprise
GERON CORP Price and EPS Surprise | GERON CORP Quote
Earnings Whispers?
Our proven model does not conclusively show that Geron is likely to beat earnings. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here, as you will see below.
Zacks ESP: Earnings Surprise Prediction or Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. Both the Most Accurate estimate and the Zacks Consensus Estimate for Geron are a loss of 7 cents per share.
Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks of #1, #2 and #3 have a significantly higher chance of beating earnings. The sell-rated stocks (#4 and #5) should never be considered going into an earnings announcement.
Other Stocks to Consider
Here are a couple of health care companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
The Earnings ESP for Exelixis, Inc. (EXEL - Free Report) is +3.70% and it carries a Zacks Rank #3. The company is expected to release second-quarter results on Aug 3.
Fate Therapeutics, Inc. (FATE - Free Report) has an Earnings ESP of +12.9% and carries a Zacks Rank #3. It is expected to release second-quarter results on Aug 3.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>